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Bendamustine is a chemotherapeutic agent discov-ered in the erstwhile East Germany. The drug re-mained unrecognized in the rest of the world until 
the last decade.1 It was re-introduced as an effective agent 
first in relapsed lymphoproliferative disorders and later 
in the frontline setting by studies conducted in the last 
two decades.1-5 It was re-introduced and later approved in 
the treatment og lymphoproliferative disorders. Generic 
bendamustine became available in India beginning in 
2009. We describe our preliminary experience (responses 
and side effect profile) with the use of this agent in chronic 
lymphocytic leukemia (CLL) and follicular lymphoma 
(FL) from a tertiary cancer hospital in South India. 
METHODS
We retrospectively analyzed all patients with lympho-
proliferative disorders who received bendamustine. We 
looked at the diagnosis, previous therapies, indication 
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BACKGROUND AND OBJECTIVES: Bendamustine has been recently approved for the treatment of low-grade 
lymphoproliferative disorders. There is little data on the effectiveness or toxicity of this drug outside the trial set-
ting. This is the first report on the use of bendamustine from the Indian subcontinent. 
SETTINGS AND DESIGN: Retrospective descriptive analysis of response and side effects of bendamustine in 
eight patients with chronic lymphocytic leukemia and eight patients with follicular lymphoma. 
METHODS: Data was collated from a review of case records. We examined any association between side effects 
and clinical parameters. 
RESULTS: The median age of patients was 52 years and three-quarters had received prior treatment with alkyl-
ators or fludarabine. Three different protocols of bendamustine were used (single agent, in combination with 
rituximab or in combination with vincristine and prednisolone). The overall response rate was 80% (47% com-
plete response, 33% partial response, and 20% progressive disease). The drug was well tolerated with very few 
grade 3/4 toxicities. More than half the patients (9/16) developed a characteristic erythematous, papular skin 
rash that resolved after completion of chemotherapy. 
CONCLUSION: Bendamustine is a safe and useful addition to the drug arsenal against lymphoproliferative dis-
orders. A peculiar skin rash was the commonest side effect noted in Indian patients treated with this drug.
for using bendamustine, the particular protocol used, 
toxicities and the response.  Response evaluations were 
done 4 to 6 weeks after completion of planned therapy 
using standard response evaluation criteria.6,7 Since we 
noted skin rash as a side effect in a majority of the pa-
tients, we performed a chi-square analysis to look for 
any association of this particular toxicity with other pa-
rameters. Necessary approval from the Institute Board 
was obtained to access the patient data.
RESULTS
Sixteen patients (Table 1) were started on bendamus-
tine and completed treatment during the period of 
analysis (December 2009 to September 2010). There 
were 8 patients with CLL and 8 with FL. The median 
age was 52.5 years (34-70 years) and 12/16 (75%) were 
males. Four patients (25%) received bendamustine as 
first-line therapy while 12 (75%) received it for progres-
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sive/relapsed disease. Three patients had been previ-
ously exposed to fludarabine while 7 had received prior 
rituximab. Single agent bendamustine was used in 8 pa-
tients (50%), 5 (31%) received BR (bendamustine and 
rituximab) and 3 (18%) received BOP (bendamustine, 
vincristine, prednisolone). Rituximab was offered in all 
patients, but only 5 could afford it. The median time 
from initial diagnosis to starting bendamustine was 25 
months (range: 0-82 months). The median number of 
cycles delivered were 6 (range 1-8). Bendamustine was 
used at a dose of 90-100 mg/m2 on days 1 and 2 except 
in patients with CLL with low blood counts, where it 
was dosed at 70 mg/m2 on days 1 and 2 of every cycle. 
Whenever rituximab was used it was given prior to the 
infusion of bendamustine. All cycles were given once in 
4 weeks. 
Two patients discontinued therapy before the con-
clusion of planned treatment; 1 had progressive disease 
and 1 defaulted therapy after just 1 cycle. Among the 
8 CLL patients, 4 achieved complete response (CR), 2 
partial response (PR), 1 had progressive disease (PD) 
and 1 was not evaluable. Among the 8 FL patients, 3 
achieved CR, 3 PR and 2 had PD. The overall response 
rate (out of the 15 evaluable patients) was 80%. Seven 
patients achieved CR (47%), 5 achieved PR (33%) and 
3(20%) had progressive disease.  All 4 patients who re-
ceived BR combination had responded (2 PRs and 2 
CRs) while the response was seen in 8/11 (5 CRs and 
3 PRs) patients receiving B or BOP regimes. Among 
the 6 evaluable patients who had failed prior ritux-
imab-based regimes, 5 responded (including 4 CRs) to 
bendamustine therapy. 
The commonest side effect was skin rash which was 
seen in 9/16 patients. The pattern of rash was similar 
in all patients who developed it. The rash emerged as 
a polymorphous, erythematous, occasionally pruritic, 
cutaneous papules and plaques (Figure 1a), mostly in-
volving the exposed areas of limbs, and trunk (Figure 
1b). The face was involved in some patients. Secondary 
infection subsequent to excoriation caused by scratch-
ing was occasionally noted (Figure 1c). The rash ap-
peared 7-10 days after the previous bendamustine 
cycle. It occurred after a single cycle in 2 patients, af-
ter 4 cycles in 2 patients, after 5 cycles in 3 patients 
and after 6 cycles in 2 patients.  Biopsy of these lesions 
(done only in the first 2 patients) showed a few chronic 
inflammatory cells around the adnexal structures in 
dermis. There were no atypical cells (Figure 2a and b). 
None of these patients had skin lesions prior to start-
ing bendamustine, including those who had a long du-
ration of disease and earlier exposure to other lines of 
chemotherapy. There was no correlation between the 
development of the rash and dose of the drug, sex, pre-
vious therapies, type of protocol (single agent benda-
mustine versus BOP versus BR) used, or the response 
to therapy (chi-square test, values not shown). No 
eosinophilia was noted in any of the patients. Rashes 
were treated symptomatically with oral antihistamines 
and topical emollient creams. No patient required dose 
reduction or stoppage of bendamustine because of the 
rashes. Since the rash occurred exclusively in exposed 
areas we empirically advised all patients to take steps to 
cover all parts of the body. 
The other common toxicity was myelosuppression: 
Pt 
no
Age/sex
Diag-
nosis
Time from 
diagnosisa 
(months)
No. of 
previous 
treatments 
(protocols)
Doseb Regime Responsec
1 70/M CLL 0 NIL 70 BR CR
2 50/F CLL 2 1 (CHOP) 100 BOP CR
3 55/M CLL 30 1 (R-COP) 100 B CR
4 63/M CLL 36 2 
(R-COP, F)
70 BR NE
5 34/M CLL 0 NIL 70 BR PR
6 40/M CLL 82 2 
(R-COP, F)
70 BR PR
7 36/F CLL 0 NIL 90 B CR
8 51/M CLL 54 1 (oral C) 70 BOP PD
9 60/M FL 23
2 
(COP, R-
CHOP)
90 B PR
10 55/M  FL 61 1 (COP) 90 B PD
11 61/M FL 28
2 
(*CHOP, 
R-COP)
100 B PD
12 46/M FL 10 1 (CHOP) 90 BR CR
13 54/F FL 77 2 
(CHOP, F)
90 B PR
14 50/F FL 30 1 (R-COP) 90 B CR
15 50/M FL 0 NIL 90 BOP PR
16 61/M FL 3 1 (R-COP) 90 B CR
Table 1. Baseline characteristics and response to bendamustine.
CLL: Chronic lymphocytic leukemia, FL: Follicular lymphoma, R: Rituximab, C: Cyclophosphamide, O: Vincristine, 
P: Prednisolone, F: Fludarabine, H: Doxorubicin, B: Bendamustine; CR: Complete response, PR: Partial response, 
PD: Progressive disease, SD: Stable disease;  SR: skin rashes; FN: Febrile Neutropenia; N : Neutropenia; NE: Not 
evaluable for response; a. Time from diagnosis to start of bendamustine, b. Dose of bendamustine used as mg/m2 on 
D1 and 2, c. Response to CLL was assessed by the International Working groups recommendations6 and responses to 
FL by the WHO criteria7
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four (25%) patients developed grade 3/4 neutropenia 
with 3 episodes of febrile neutropenia. Doses were 
reduced by 25% in those who developed grade 3/4 
toxicities. No cycle was delayed because of toxicity. In 
addition, 2 patients developed non-neutropenic fever 
while on bendamustine including pneumococcal lobar 
pneumonia in a 70-year-old CLL patient. The details of 
other toxicities are given in Table 2. 
DISCUSSION
This is the first report on the use of bendamustine 
from India. We found a response rate of 80% among 
patients with CLL and FL, which is similar to those 
described in other studies.2-4 This was a notable effect 
considering that three-quarters of our patients had re-
lapsed/progressive disease after previous therapies. The 
response rates were preserved even in those who had 
Figure 1. Patient 1 showing skin rashes over his upper trunk (a) on uncovered areas; similar distribution of rashes on overexposed 
areas in patient 5 (b) with rashes restricted to the areas above and below the area covered by her jacket; same patient showing 
rashes over her forearms (c) some of which have blistered and excoriated due to scratching caused by pruritus. Note the distribution 
of the rash in the forearms (exposed areas).
Figure 2. Skin biopsy from patient 5 (a) showing skin with the dermis exhibiting increased collagen deposition and scattered adnexal 
structures surrounded by lymphoid cells infiltration (4×). At a higher magnification (b) demonstrated dermal collagenization and 
periadnexal lymphoid cells infiltrate (10× H and E stain).
Toxicity N (%) Comment
Anemia 4 (25) Grade 4 in 1 patient
Thrombocytopenia 5 (31) No grade 3/4 toxicity
Neutropenia 6 (37) Grade 3/4 in 4 (25%)
Febrile neutropenia 3 (18) All episodes managed with in-patient admission 
Non-neutropenic 
fever 2 (13)
1 had lobar pneumonia, 
1 no focus
Nausea/Vomiting 5 (31) All grade 1
Fatigue 8 (50) Mostly grades 1/2 
Skin rash 9 (56) Commonest toxicity, mostly grades ½ 
Alopecia 2 (13) Both occurred in patients receiving BOP
Table 2. Side effects noted during bendamustine use (n=16).
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received prior rituximab. These excellent results were 
at the cost of significant but manageable side effects; 
25% of patients required dose modifications because 
of side effects, but there were no cycle delays and no 
one discontinued therapy because of side effects. Other 
studies have demonstrated the safety of bendamustine 
combinations and have shown that the side effects are 
lesser than standard regimes like R-CHOP when used 
in low-grade lymphomas.5 
We noted an unusual skin toxicity in 9/16 patients. 
The rash was clearly attributable to bendamustine use 
as none of the patients had skin lesions before and the 
rashes subsided after completion of chemotherapy. The 
rashes occurred regardless of the type of concomitant 
drugs used. We do not have a specific explanation for 
the pathogenesis of this rash. A hypersensitivity-like re-
action is likely considering the inflammatory response 
seen in the skin biopsies. Skin rashes, including rare ep-
isodes of Stevens-Johnson syndrome have been docu-
mented as a side effect of bendamustine (8% in CLL and 
16% in NHL); however, we could not find any literature 
on the exact nature of these manifestations.8 In one case 
report, Alamdari et al described a severe case of acute 
interface dermatitis which developed after administra-
tion of bendamustine.9 Skin lesions, which have been 
attributed to an exaggerated response to insect bites in 
exposed areas, have been described in CLL and NHL 
patients.10,11 Though many of our patients reported in-
sect bites, the histopathology did not reveal any eosino-
philic infiltration or other characteristic insect bite-like 
reactions. The other possibility is a photosensitive rash, 
which can also take the form of erythematous, papular, 
or licheniform reactions.12 
From this retrospective analysis involving a diverse 
patient profile, we conclude that bendamustine is a 
useful addition to the treatment of low-grade lympho-
proliferative disorders. Though serious adverse events, 
especially myelosuppression can occur, these are rare, 
even in elderly, heavily pre-treated patients. We noticed 
an unusual skin rash in more than half of our patients. 
Since we did not find any description of skin rashes 
similar to our findings, we recommend that future stud-
ies look for any geographical/ethnic restriction and also 
for possible correlation with disease response. 
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